<DOC>
	<DOCNO>NCT02097849</DOCNO>
	<brief_summary>Primary objective evaluate immune response vaccination tetanus diphtheria toxoid vaccine ( Td ) participant relapse form Multiple Sclerosis ( MS ) treat Tecfidera ( BG00012 ) versus treat non pegylated interferon ( IFN ) . Secondary objective evaluate immune response vaccination 23-valent pneumococcal polysaccharide vaccine ( PPSV23 ) [ mostly T cell-independent humoral response ] meningococcal polysaccharide diphtheria conjugate vaccine , quadrivalent ( MCV4 ) [ T cell-dependent neoantigen response ] .</brief_summary>
	<brief_title>Vaccination Response Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms Multiple Sclerosis .</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Key Must confirm diagnosis RRMS per 2010 McDonald criterion . Must know tetanus immunization history recent tetanus vaccination give 2 15 year prior Screening antitetanus IgG titer Screening less equal onehalf upper limit detection assay . Must stable approve dose Tecfidera ( 240 mg twice daily [ BID ] ) [ Group 1 ] ≥6 month stable approve dose nonpegylated IFN ( e.g. , Avonex , Betaseron , Rebif , Extavia ) [ Group 2 ] ≥3 month prior Day 1 . Key Clinical relapse require treatment within 30 day prior Day 1 . Pneumococcal vaccination within 5 year prior Screening . Previous exposure meningococcal vaccine . Known hypersensitivity Td , PPSV23 , MCV4 component . NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>vaccine</keyword>
	<keyword>pneumococcal</keyword>
	<keyword>meningococcal</keyword>
	<keyword>tetanus diphtheria</keyword>
	<keyword>immune response</keyword>
</DOC>